Confidential treatment has been requestedfor portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions aredesignated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. AMENDMENT NO. 2 to PROTIVA AGRICULTURAL DEVELOPMENTCOMPANY INC. OPTION AGREEMENT

EX-10.1 2 exh_101.htm EXHIBIT 10.1

Exhibit 10.1

 

 

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

AMENDMENT NO. 2 to PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC. OPTION AGREEMENT

 

 

THIS AMENDMENT NO. 2 to PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC. OPTION AGREEMENT (“Amendment No. 2”) effective as of the last date of signature hereto (“Effective Date”), is by and among Monsanto Canada, Inc., a Canadian corporation (“Monsanto Canada”), Tekmira Pharmaceuticals Corporation, a British Columbia corporation (“Tekmira”), Protiva Biotherapeutics Inc., a British Columbia corporation (“Protiva”), and Protiva Agricultural Development Company Inc., a British Columbia corporation (the “Company”).

 

WHEREAS, Monsanto Canada, Tekmira, Protiva, and Company (collectively the “Parties”) are parties to an option agreement effective January 12, 2014 (the “Agreement”); and

 

WHEREAS, Parties desire to amend Exhibit B-5(ii), OPTION SHIPMENT COMPLETION CRITERIA;

 

NOW, THEREFORE, in consideration of the above, the Parties hereby agree to amend the Agreement as follows:

 

  1. Exhibit B-5(ii), OPTION SHIPMENT COMPLETION CRITERIA in the Agreement shall be replaced in its entirety by the amended and restated OPTION SHIPMENT COMPLETION CRITERIA attached hereto.

Upon execution, this Amendment No. 2 shall be made a part of the Agreement. Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and effect.

 
 

IN WITNESS WHEREOF, the parties hereto have executed or caused this Amendment No. 2 to be executed by their respective officers or other representatives duly authorized.

 

 

 

 

 

PROTIVA BIOTHERAPEUTICS INC.

 

 

 

 

By: /s/ Bruce Cousins

Name: Bruce Cousins

Title:

Address:

 

 

PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.

 

 

 

By: /s/ Bruce Cousins

Name: Bruce Cousins

Title:

Address:

 

 

 

 

 

   

TEKMIRA PHARMACEUTICALS CORPORATION

 

 

 

By: /s/ Bruce Cousins

Name: Bruce Cousins

Title:

Address:

 

MONSANTO CANADA, INC.

 

 

 

 

By: /s/ Robert M. McCarroll

Name: Robert M. McCarroll, Ph. D.

Title: Authorized Signatory

Address:

 

 

 

 

 
 

 

 

EXHIBIT B-5(ii)

 

OPTION SHIPMENT COMPLETION CRITERIA

 

 

[***]